Investment
Features
FeesSafety
Academy
More
Pluang+

Terreno Realty posts strong Q2 with 11.1% revenue growth and 97.6% occupancy, keeps Buy rating.

Analyst Insights
15 Sep 2026
Seeking Alpha
View Source
Bullish
Terreno Realty posts strong Q2 with 11.1% revenue growth and 97.6% occupancy, keeps Buy rating.

Terreno Realty Corporation reported solid Q2 results with 11.1% revenue growth and 9.4% growth in funds from operations per share. The company maintained a high occupancy rate of 97.6% and achieved 27.7% cash rent increases on new leases. It continues disciplined capital recycling with acquisitions at a 5.3% cap rate and a conservative net debt to EBITDA ratio of 2.5x, supported by Moody's Baa1 credit rating. Dividend growth of 9.6% was noted, though the payout now exceeds adjusted funds from operations, which investors should watch closely going forward.

Terreno Realty Corporation's strong Q2 results provide context for readers. For those following the Real Estate sector, here is Pluang's market snapshot as of Sep 15, 2026 20:33 WIB: out of 22 priced US Real Estate stocks, 2 rose and 20 fell. Notable movers include Prologis Inc (PLD) at USD 134.43 with a -0.54% change, VICI Properties Inc (VICI) at USD 24.91 with a -0.54% change, and Simon Property Group Inc (SPG) at USD 204.05 with a -0.45% change.

More News

Hormel Foods price target cut to $23 amid hopes for valuation rebound despite 50% share drop.

Hormel Foods price target cut to $23 amid hopes for valuation rebound despite 50% share drop.

BNP Paribas lowered Hormel Foods' price target from $26 to $23, indicating a potential 16.2% upside from its current price of around $19.80. Despite a 50.5% decline in its share price over five years, Hormel Foods remains attractive for dividend inve...

Analyst Insights
Neutral
1 hour ago
Barclays rates Becton Dickinson 'Underweight' amid $3B U.S. manufacturing partnership

Barclays rates Becton Dickinson 'Underweight' amid $3B U.S. manufacturing partnership

Barclays initiated coverage of Becton, Dickinson and Company (BDX) with an "Underweight" rating, indicating a cautious outlook for the medical technology stock. BDX is partnering with the U.S. government to boost domestic manufacturing and strengthen...

Market News
Bearish
1 hour ago
Morgan Stanley raises Eli Lilly price target to $1,430, signaling 20.8% potential upside.

Morgan Stanley raises Eli Lilly price target to $1,430, signaling 20.8% potential upside.

Morgan Stanley increased its price target for Eli Lilly to $1,430 from $1,419, maintaining an Overweight rating. This new target implies a potential upside of about 20.8% from the current share price of around $1,184. The adjustment reflects updated ...

Analyst Insights
Bullish
2 hours ago
Arthur J. Gallagher sees 6% organic growth; analysts split on price targets amid mixed outlook.

Arthur J. Gallagher sees 6% organic growth; analysts split on price targets amid mixed outlook.

Arthur J. Gallagher expects about 6% organic growth in Q3, driven by strong client retention and new business despite easing property insurance pricing. Cantor Fitzgerald lowered its price target to $280, below the $288 average from 19 analysts who m...

Analyst Insights
Bullish
3 hours ago
Zscaler's price target raised to $255 on strong AI-driven cybersecurity demand and growth outlook.

Zscaler's price target raised to $255 on strong AI-driven cybersecurity demand and growth outlook.

Needham raised Zscaler's price target to $255, citing strong demand for AI-related cybersecurity solutions. Zscaler aims to exceed $8 billion in annual recurring revenue by fiscal 2031, driven by increasing needs to protect against AI-powered cyberat...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App